IM Cannabis Corp Announces Branded Strain’s Efficacy in Reducing Migraines

Logo: IM Cannabis Corp

TORONTO and GLIL YAM, Israel – IM Cannabis Corp. (the “Company” or “IMC”) (CSE:IMCC), one of the world’s pioneering medical cannabis companies with operations in Israel and across Europe, announced today that a recent peer-reviewed study conducted by Professor Dedi Meiri at the Technion – Israeli Institute of Technology (“Technion”) investigating the associations between phytocannabinoid treatment and migraine frequency, found that medical cannabis results in long-term reduction of migraine frequency in over 60% of treated patients1. The study also found that medical cannabis is associated with less disability and lower antimigraine medication intake. Furthermore, Technion’s research indicated that two strains used in the study (IMC’s London and Tel-Aviv strains) were found to be specifically effective.

“At IMC, we have high conviction that the development of evidence-based research in medical cannabis will lead to a new generation of medical products to treat a variety of indications and illnesses over the long-term. We will continue to partner with visionaries and leading researchers such as Professor Dedi Meiri and Technion to advance research and development of medical cannabis as it aligns strongly with our vision of leadership in global medical cannabis,” said Oren Shuster, CEO of IMC. “The results of this study follow our announcement last week of a binding term sheet with MGC Pharmaceuticals Ltd. to distribute CannEpil in Israel for the treatment of refractory epilepsy. As we continue to develop relationships with innovators in research and development, we plan to use our global distribution network to bring a range of high-quality medical cannabis products to patients across the world.”


Professor Dedi Meiri, commented, “In the past five years, my lab, together with the main growers in Israel, have been running the Israeli database project. As part of this project, we have been testing the associations between phytocannabinoid treatment and migraine frequency. In this work we observed that 89% of the respondents reported lower current migraine disability and lower negative impact, and lower rates of opioid and triptan consumption. Moreover, we were able to demonstrate that the respondents consumed cannabis strains with higher doses of the phytocannabinoid ms_373_15c and lower doses of the phytocannabinoid ms_331_18d. Two of the most impactful strains in the study were IMC branded strains, Tel-Aviv and London.”

About IM Cannabis Corp.
IMC is an international medical cannabis company, and a well-known Israeli brand of medical cannabis products. In Europe, IMC has established a medical cannabis operation first with its distribution subsidiary in Germany and augmented by strategic agreements with certified EU-GMP Standard suppliers, making it one of the only medical cannabis companies with fully integrated operations in Europe. IMC intends to leverage its operational experience and brand to establish a foothold in emerging medical cannabis markets including Germany, Portugal and Greece. IMC’s core Israeli business includes offering branding, know-how and other intellectual property-related services to the Israeli medical cannabis market. Its key assets in Israel include commercial agreements with licensed producers and an option to purchase licensed entities. IMC has developed proprietary processes in its operations and is active in developing and investing in innovative technology for global medical cannabis consumers leveraging its reputation and expertise in the medical cannabis sector.

About Technion
Technion – Israel Institute of Technology, consistently ranked among the world’s top science and technology research universities, is Israel’s first university. Since its founding in 1912, the institute has educated generations of engineers, architects, and scientists who have played a key role in laying the State of Israel’s infrastructure and establishing its crucial high-tech industries. Beginning with 17 students, Technion has been Israel’s primary source of technological manpower and the nation’s largest comprehensive academic center for advanced science and technology education, as well as applied research. In addition, Technion is one of only a handful of technology institutes in the world with an affiliated medical school.Technion has 18 academic departments in engineering, natural sciences, medicine and architecture, as well as 60 research centers. Students may choose from some 50 undergraduate and 82 graduate academic programs. There are currently close to 14,000 students at the Technion (~9,300 BSc, ~2,800 MSc, ~1,000 PhD, and ~ 660 MD). To date, Technion has awarded around 100,000 degrees. Technion graduates have brought the unique skills and penchant for innovation which helped conceive and consolidate the modern State of Israel – commonly acknowledged to be the “Start-up Nation.”The staff of the Technion includes 620 faculty members; 1,000 technical and administrative staff; 250 clinicians; and 950 adjuncts and instructors.

Previous article3 Keys to Workplace Happiness
Next articleNCIA Offering Free Membership to Social Equity Applicants and Licensees